Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Move To Consolidate Translational Programs Is Not The Big Shakeup It's Made Out To Be, Agency Says

Executive Summary

The National Institutes of Health's proposed National Center for Advancing Translational Sciences reflects neither a shakeup of existing NIH programs nor any intent to create an agency that functions like a drug company, NIH officials say.

You may also be interested in...



NIH Repurposing Of Failed Compounds Could Begin Soon; NCATS Plans Pilots

The National Center for Advancing Translational Science soon may have an agreement with one or more firms to allow research to test abandoned compounds for new uses, NIH Deputy Director for Science, Outreach and Policy Kathy Hudson says. NIH has sought, and will continue to seek, industry input on where NCATS should put its efforts to speed translation of drugs from the bench to the market, she notes.

Tax Incentives For Biomedical Industry Are Focus Of Multiple Bills In Congress

Tax incentives for the life sciences industry have a lot of allies in Congress, but any traction on reforms probably awaits broader movement on major tax or economic legislation

Tax Incentives For Biomedical Industry Are Focus Of Multiple Bills In Congress

Tax incentives for the life sciences industry have a lot of allies in Congress, but any traction on reforms probably awaits broader movement on major tax or economic legislation

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel